These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2008-000972-25 A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase 3 study to compare efficacy and safety of ma... 2017-03-03 bad-data
Listed as ongoing, but also has a completion date 2008-000973-40 A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in tr... 2018-05-30 bad-data
Listed as ongoing, but also has a completion date 2008-000974-18 A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, Phase III study to compare efficacy and safety of masitinib at 9 mg/kg/day in combination with gemcitabine, ... 2012-03-26 bad-data
Ongoing 2009-017918-69 A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatme... not-yet-due
Listed as ongoing, but also has a completion date 2009-017930-35 A prospective, multicenter, randomised, double-blind, placebocontrolled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 6 mg/kg/day in combination with bortezomib and d... 2017-01-16 bad-data
Completed, but no date 2010-018982-43 A prospective, multicenter, open-label, uncontrolled, two-parallel group, phase 1/2 study to evaluate safety and efficacy of masitinib at 9 mg/kg/day in monotherapy and in combination with dacarbazine... bad-data
Ongoing 2010-020603-79 A prospective, multicentre, randomised, double-blind, placebo-controlled, 3-parallel groups, phase 2 study to evaluate efficacy and safety of 12 weeks treatment with masitinib versus placebo in patien... not-yet-due
Listed as ongoing, but also has a completion date 2010-020803-63 A prospective, multicenter, randomised, double-blind, placebo-controlled, 2-parallel groups, Phase 3 study to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the trea... 2015-02-04 bad-data
Not reported 2010-020992-21 A 24-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 3-parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib at 3 and 4.5 mg/kg/da... 2017-03-10 due-trials
Ongoing 2010-021091-28 A multicenter, randomised, open-label, three-parallel groups, phase 2-3 study to evaluate the efficacy and safety of masitinib with dexamethasone, gemcitabine with dexamethasone and the combination of... not-yet-due
Other 2010-021218-50 A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease not-yet-due
Other 2010-021219-17 A 96-week, prospective, multicenter, randomised, double-blind, placebo-controlled, 2-parallel groups, Phase 3 study to compare efficacy and safety of masitinib 4.5 mg/kg/day versus placebo in the trea... not-yet-due
Other 2010-021495-29 A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib at 6 mg/kg/day versus placebo in pat... not-yet-due
Other 2010-022620-77 A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with etoposide, or masitinib in combination with irinoteca... not-yet-due
Listed as ongoing, but also has a completion date 2010-022646-24 A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with gemcitabine or carboplatin or capecitabine in patient... 2017-02-11 bad-data
Completed, report not yet due 2010-022744-21 A 12-week, proof of concept prospective, randomized, double blind, phase 2a study to compare safety and efficacy of masitinib to placebo in the treatment of mood disorders in patients with antidepress... 2018-05-08 not-yet-due
Listed as ongoing, but also has a completion date 2010-024423-24 A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2/3 Study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients s... 2018-03-05 bad-data
Completed, but no date 2010-024424-26 A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo on cognitive impairment associate... bad-data
Other 2011-001790-41 A prospective, multicenter, randomised, open-label, active controlled, 2 parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal s... not-yet-due
Listed as ongoing, but also has a completion date 2012-003735-32 A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients with... 2018-04-30 bad-data
Listed as ongoing, but also has a completion date 2012-004222-25 A 12-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 2-parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to placebo, in the tr... 2017-02-10 bad-data
Listed as ongoing, but also has a completion date 2012-005586-13 A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with seve... 2018-05-08 bad-data
Listed as ongoing, but also has a completion date 2013-000490-79 A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fl... 2017-02-10 bad-data
Other 2013-000491-14 A prospective, multicenter, open-label, centrally allocated, active-controlled, phase 2/3 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alon... not-yet-due
Ongoing 2013-000493-30 A prospective, multicentre, open-label, randomized, active-controlled, 3 parallel groups, phase 2-3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-flu... not-yet-due
Other 2013-000809-23 A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo in c... not-yet-due
Other 2013-002293-41 A prospective, multicenter, double-randomised, double-blind, 2-parallel groups, phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination with gemcitabine, to gemc... not-yet-due
Completed, report not yet due 2013-003740-23 A prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2b/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients ... 2018-05-03 not-yet-due
Ongoing 2013-004162-34 A prospective, multicenter, randomized, double-blind, placebo-controlled, two-parallel groups, phase III clinical trial to compare the efficacy and safety of masitinib to placebo in patients with loca... not-yet-due
Ongoing 2015-000897-36 A prospective, multicentre, double-blind, randomized, placebo-controlled, phase 3 study to evaluate efficacy and safety of masitinib with irinotecan in patients with advanced-stage esophagogastric ade... not-yet-due
Ongoing 2016-001447-39 A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase 3 study to compare efficacy and safety of ma... not-yet-due